MedTrace Logo

Comparison of Mean Duration of Post Operative Analgesia Following QL-2 Block vs QL-3 Block Using Ropivacain 0.25% in Patients Undergoing Unilateral Inguinal Hernia Repair

NCT07200076 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2025-10-06

No results posted yet for this study

Summary

To compare the mean dulation of post operative analgesia following QL2 block (posterior quadratus lumborum block) and the QL3 block (transmuscular quadratus lumborum block) using ropivacaine 0.25% in patients undergoing unilateral inguinai hernia repair.

Rationale of the proposed study is to find an optimal approach for quadratus lumborum block (QLB) in the context of local population as no local study has already been carried out for our population. The study seeks to determine which approach provides superior postoperative pain relief and aspires to establish a clear rationale for the application of one technique over the other in local population. By uncovering the strengths and limitations of each approach, the study intends to guide local clinicians in making informed decisions for optimizing postoperative pain management strategies. The outcomes of this study are anticipated to have a substantial impact on clinical practice, potentially leading to improved patient outcomes, reduced opioid consumption, and enhanced patient comfort following inguinal hernia repair surgeries in local settings.

Conditions

  • Inguinal Hernia Unilateral

Interventions

PROCEDURE

Quadratus Lumborum (QL) Block

In the QLB-2 approach, a needle will be inserted in-plane from anterior to posterior, directed towards the posterior QL muscle border, and a 20 ml solution of 0.25% ropivacaine will be injected. For the QLB-3 approach, the needle will be inserted in-plane from anterior to posterior, traversing the QL muscle's proper fascia to target the plane between the QL and PM muscles, and a 20 ml solution of 0.25% ropivacaine will be injected.

Sponsors & Collaborators

  • Quaid-e-Azam Medical College

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-01
Primary Completion
2024-12-30
Completion
2025-01-28

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07200076 on ClinicalTrials.gov